Hepatocellular carcinoma (HCC) treatment has entered the immunotherapy era, characterized by multiple systemic and locoregional therapeutic options. Understanding how each modality modulates the tumor immune microenvironment (TIME) is essential to optimize treatment strategies. The cancer-immunity cycle provides a conceptual basis for antitumor immunity, consisting of a priming phase involving antigen release and T cell activation, and an effector phase characterized by cytotoxic T cell-mediated tumor elimination. Immune checkpoint inhibitor-based combinations play a central role in HCC treatment. Anti-programmed death ligand-1 plus anti-vascular endothelial growth factor (VEGF) therapy primarily activates the effector phase by reducing regulatory T cells and macrophages and enhancing cytotoxic T cell infiltration. In contrast, cytotoxic T lymphocyte-associated antigen 4 blockade-based regimens primarily promote the priming phase by activating CD4+ T cells and dendritic cells. Molecular-targeted agents also modulate the TIME. VEGF inhibition commonly reduces immunosuppressive cell populations, lenvatinib enhances cytotoxic T cell activation through fibroblast growth factor inhibition, and cabozantinib promotes dendritic cell-mediated immune activation via AXL inhibition. Locoregional therapies, including transarterial therapies, stereotactic body radiotherapy, and transarterial radioembolization with yttrium 90, induce tumor injury, release tumor-associated antigens, and activate inflammatory signaling. In this review, we propose the concept of “strategic driving of the cancer-immunity cycle,” in which treatment selection and sequencing are guided by their ability to activate distinct phases of the cycle. This concept may provide a rational strategy to maximize antitumor efficacy in HCC.
The emergence of systemic therapies has ushered in an era of chemo-diversity for hepatocellular carcinoma, in which drug sequencing is pivotal for maximizing outcomes. Among available agents, lenvatinib is notable for its potent anti-angiogenic and immunomodulatory properties. This review proposes a structured building-block strategy for optimizing sequential drug therapy, conceptualizing each treatment line as a block that contributes cumulatively to survival, and grounding the discussion in clinical insights from lenvatinib administration. We comprehensively evaluated clinical trials, preclinical investigations, and real-world data to identify actionable approaches that enhance tolerability and prolong progression-free survival, with a particular focus on mitigating adverse events, optimizing dosing schedules, and integrating with transarterial therapies. Five refinements emerge as central to maximizing therapeutic benefit: early detection and classification of adverse events, use of supportive agents such as L-carnitine and branched-chain amino acids, structured telephone follow-up, optimization of dosing schedules, including weekend-off regimens, and strategic combination with transarterial therapy. In addition, rationale-based sequencing and clinically relevant switching criteria that extend beyond RECIST are summarized. Collectively, these measures increase the height of each therapeutic block, thereby contributing to cumulative survival within the building-block strategy. In the current era of chemo-diversity, lenvatinib remains a cornerstone agent when accompanied by these clinical refinements. The review provides a practical and conceptual framework for enhancing efficacy through structured sequencing, proactive adverse-event mitigation, and synergistic locoregional strategies, with broad applicability to real-world clinical practice.
Citations
Citations to this article as recorded by
Strategic driving of the cancer-immunity cycle in HCC: roles of immune, molecular-targeted, and locoregional therapies Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Journal of Liver Cancer.2026; 26(2): 220. CrossRef